What is the equity of Immuron this year?
Immuron has equity of 19.62 M AUD this year.
Immuron Equity 2024
Immuron Equity
19.62 M AUD
Ticker
IMC.AX
ISIN
AU000000IMC7
WKN
A0RDPK
In 2024, Immuron's equity was 19.62 M AUD, a -15.36% increase from the 23.18 M AUD equity in the previous year.
Immuron Aktienanalyse
What does Immuron do?
Immuron Ltd was founded in 1994 and is headquartered in Melbourne, Australia. The company specializes in researching, developing, and marketing immunotherapy products. Immuron utilizes its patented technologies to develop and manufacture polyclonal antibodies and hyperimmune serums. The business model of Immuron focuses on selling immunotherapy products. The company concentrates on developing innovative products that address high medical needs and significantly improve the health of patients. Immuron operates in three divisions: gastrointestinal health, veterinary medicine, and infection control. Within these divisions, Immuron offers a variety of products tailored to specific needs. Gastrointestinal health is one of Immuron's key divisions. The company utilizes its expertise to develop products that protect and strengthen the human and animal intestine. Products in the gastrointestinal division include Travelan®, which is used for the prevention and treatment of traveler's diarrhea, and IMM-124E, which is used to treat inflammatory bowel diseases. It is also available in veterinary medicine. Veterinary medicine is another important pillar of Immuron's business. The company offers products tailored to the needs of animals. One notable product is the Immuron Canine® product line, used in the treatment of diarrhea in dogs. Additionally, the company has developed application-oriented research programs in infection control to aid veterinarians in improving the health of their animals. Immuron also has a division focused on infection control. The company develops and manufactures therapeutic products that target infections such as Helicobacter pylori and C. difficile. These products can contribute to reducing the use of antibiotics and antibiotic resistance. Over the years, Immuron has successfully brought several products to market. For example, Travelan® has been approved in Australia, Europe, and North America. Additionally, IMM-124E has been successfully tested in clinical studies in Canada and the United States and is currently undergoing the approval process in Europe. Overall, the company has a promising pipeline of products ready for market launch or phase II and III trials. These products have the potential to improve healthcare and enhance the quality of life for patients worldwide. Immuron has a strong foundation in immunotherapy research, which benefits the company in developing novel therapeutic options. Currently, Immuron is in a phase of growth, and it is likely that the company will achieve further success in the future. Immuron ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Immuron's Equity
Immuron's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Immuron's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Immuron's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Immuron's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Immuron’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Immuron stock
What was the equity of Immuron compared to the previous year?
The equity of Immuron has increased/decreased by -15.36% decreased compared to the previous year.
What impact does a high equity have on investors of Immuron?
A high equity is advantageous for investors of Immuron as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Immuron?
A low equity can be a risk for investors of Immuron, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Immuron affect the company?
An increase in equity of Immuron can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Immuron affect the company?
A reduction in equity of Immuron can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Immuron?
Some factors that can affect the equity of Immuron include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Immuron so important for investors?
The equity of Immuron is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Immuron take to change the equity?
To change equity, Immuron can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Immuron pay?
Over the past 12 months, Immuron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immuron is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immuron?
The current dividend yield of Immuron is .
When does Immuron pay dividends?
Immuron pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immuron?
Immuron paid dividends every year for the past 0 years.
What is the dividend of Immuron?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immuron located?
Immuron is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immuron kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immuron from 9/12/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did Immuron pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of Immuron in the year 2023?
In the year 2023, Immuron distributed 0 AUD as dividends.
In which currency does Immuron pay out the dividend?
The dividends of Immuron are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immuron
Our stock analysis for Immuron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immuron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
